Microtubule-binding agents: a dynamic field of cancer therapeutics

被引:1418
作者
Dumontet, Charles [1 ,2 ]
Jordan, Mary Ann [3 ,4 ]
机构
[1] Fac Rockefeller, INSERM 590, F-69008 Lyon, France
[2] Univ Lyon 1, ISPB, F-69003 Lyon, France
[3] Univ Calif Santa Barbara, Dept Mol Cellular & Dev Biol, Santa Barbara, CA 93106 USA
[4] Univ Calif Santa Barbara, Neurosci Res Inst, Santa Barbara, CA 93106 USA
关键词
CELL LUNG-CANCER; PHASE-I TRIAL; METASTATIC BREAST-CANCER; ADVANCED SOLID TUMORS; III BETA-TUBULIN; COMBRETASTATIN A4 PHOSPHATE; VASCULAR-TARGETING AGENT; ADMINISTERED INDIBULIN D-24851; RESISTANCE-ASSOCIATED PROTEIN; REFRACTORY PROSTATE-CANCER;
D O I
10.1038/nrd3253
中图分类号
Q81 [生物工程学(生物技术)]; Q93 [微生物学];
学科分类号
071005 ; 0836 ; 090102 ; 100705 ;
摘要
Microtubules are dynamic filamentous cytoskeletal proteins composed of tubulin and are an important therapeutic target in tumour cells. Agents that bind to microtubules have been part of the pharmacopoeia of anticancer therapy for decades and until the advent of targeted therapy, microtubules were the only alternative to DNA as a therapeutic target in cancer. The screening of a range of botanical species and marine organisms has yielded promising new antitubulin agents with novel properties. In the current search for novel microtubule-binding agents, enhanced tumour specificity, reduced neurotoxicity and insensitivity to chemoresistance mechanisms are the three main objectives.
引用
收藏
页码:790 / 803
页数:14
相关论文
共 217 条
[1]   The novel microtubule-interfering agent TZT-1027 enhances the anticancer effect of radiation in vitro and in vivo [J].
Akashi, Y. ;
Okamoto, I. ;
Suzuki, M. ;
Tamura, K. ;
Iwasa, T. ;
Hisada, S. ;
Satoh, T. ;
Nakagawa, K. ;
Ono, K. ;
Fukuoka, M. .
BRITISH JOURNAL OF CANCER, 2007, 96 (10) :1532-1539
[2]   Superior Antitumor Activity of SAR3419 to Rituximab in Xenograft Models for Non-Hodgkin's Lymphoma [J].
Al-Katib, Ayad M. ;
Aboukameel, Amro ;
Mohammad, Ramzi ;
Bissery, Marie-Christine ;
Zuany-Amorim, Claudia .
CLINICAL CANCER RESEARCH, 2009, 15 (12) :4038-4045
[3]  
Alli E, 2002, CANCER RES, V62, P6864
[4]   The case for survivin as a regulator of microtubule dynamics and cell-death decisions [J].
Altieri, Dario C. .
CURRENT OPINION IN CELL BIOLOGY, 2006, 18 (06) :609-615
[5]   Progress in the development and acquisition of anticancer agents from marine sources [J].
Amador, ML ;
Jimeno, J ;
Paz-Ares, L ;
Cortes-Funes, H ;
Hidalgo, M .
ANNALS OF ONCOLOGY, 2003, 14 (11) :1607-1615
[6]  
Anderl Janet L, 2009, J Vis Exp, DOI 10.3791/1173
[7]   Assessment of pharmacodynamic vascular response in a phase I trial of combretastatin A4 phosphate [J].
Anderson, HL ;
Yap, JT ;
Miller, MP ;
Robbins, A ;
Jones, T ;
Price, PM .
JOURNAL OF CLINICAL ONCOLOGY, 2003, 21 (15) :2823-2830
[8]  
Anthony S. P., 2008, J CLIN ONC ABSTR, V26, P2531, DOI DOI 10.1200/JCO.2008.26.15SUPP1.2531
[9]   Peripheral nerve damage associated with administration of taxanes in patients with cancer [J].
Argyriou, Andreas A. ;
Koltzenburg, Martin ;
Polychronopoulos, Panagiotis ;
Papapetropoulos, Spiridon ;
Kalofonos, Haralabos P. .
CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY, 2008, 66 (03) :218-228
[10]   Weekly administration of sagopilone (ZK-EPO), a fully synthetic epothilone, in patients with refractory solid tumours: results of a phase I trial [J].
Arnold, D. ;
Voigt, W. ;
Kiewe, P. ;
Behrmann, C. ;
Lindemann, S. ;
Reif, S. ;
Wiesinger, H. ;
Giurescu, M. ;
Thiel, E. ;
Schmoll, H-J .
BRITISH JOURNAL OF CANCER, 2009, 101 (08) :1241-1247